13.9C
Delhi
Monday, January 18, 2021

Yet to receive licence to export Covishield: SII

- Advertisement -

covishield1By Ashish Srivastava, (IANS) The Serum Institute of India (SII) clarified on Monday that the company is yet to receive the permission from the authority here to export its Covid-19 vaccine to other nations, the company official told IANS.

The clarification has come after it was reported in the media that India has barred the company from exporting its vaccine for several months.

However, IANS was told that the permission has not yet been granted for exporting the vaccine.

The company, whose Covid-19 vaccine ‘Covishield’, which is developed from the master seed of AstraZeneca/Oxford Covid vaccine, received emergency authorisation approval in the country by Drug Controller General of India (DCGI) on Sunday.

The same day, the company was granted the permission to manufacture its vaccine by the DCGI.

Adar Poonawalla, SII’s CEO was reported saying that ‘the company received the emergency authorisation approval on the condition that it doesn’t export the shots to ensure that vulnerable populations in India are protected’.

READ ALSO:  Mild infection good sign, shows immune system responding to vax: AIIMS chief

He also said the Serum Institute was in the process of signing a larger contract with Covax for 300 million-400 million doses of the vaccine. That is apart from the two existing orders of 100 million doses each for the vaccine developed by Oxford University and AstraZeneca, and another one from Novovax. He said the deal would be finalised in the coming weeks.

IANS has sent a query regarding the company’s application to receive the licence to export and the orders placed till now from the other nations.

Commenting on Poonawaala’s statement reported in the media, Dr. Soumyadeep Bhaumik, public health expert at the George Institute for Global Health, said that for now, it is a reasonable policy from the government to protect our own citizens.

READ ALSO:  Normalcy may return by winter 2021, says Covid vaccine creator

“Considering the context in which high-income countries have already stocked the vaccine doses which is way more than the requirement of their population, I think it’s a reasonable policy to protect our own citizens first. We need to have our own health security first before we look for other aspects,” he said.

READ ALSO:  Russian vaccine arrives in India for human clinical trial

However, Bhaumik also added that the Centre must revisit the policy when the production of the vaccine reaches a satisfactory level.

“As of now it makes sense when no vaccines are being made. However, when productions are scaled up, this policy must be revisited. We must recognise that we are not safe until our neighbours and other lower-middle-income countries are safe as well,” he said.

Source: IANS

India Updates
India Updates is an independent news & Information website. Follow us for regular updates on News and Information.

Follow Us On

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Trending Topics In India

Covid 19 India Updates

Trending News In India

Trending Showbiz

Trending Sports

Latest Trending News In India

Parliamentary panel summons FB, Twitter officials on Jan 21

New Delhi, Jan 17 (IANS) The Parliamentary Committee on Information Technology has issued summons to officials of Facebook and Twitter for January 21, to...

447 adverse events across India post-vaccination, 3 serious

New Delhi, Jan 17 (IANS) A total of 447 Adverse Events Following Immunisation (AEFI) have been reported in the last two days of the...

New-age insurance, green energy stocks in queue for Nifty50 entry

Mumbai, Jan 17 (IANS) New-age stocks from insurance, green energy and internet space are in the queue to enter benchmark Nifty50 index, which reflects...

Centre-farmers’ standoff will resolve through dialogues: Vice Prez

New Delhi, Jan 17 (IANS) Vice President M. Venkaiah Naidu on Sunday said that the current standoff between the protesting farmers and the Centre...